The current stock price of MTFB is 0.105 null. In the past month the price decreased by -33.92%. In the past year, price decreased by -98.25%.
Motif Bio plc is a biopharmaceutical company. It engaged in the research and development of antibiotics for serious and life-threatening infections caused by multi-drug resistant bacteria. The company's product pipeline includes Iclaprim, REVIVE-1 and REVIVE-2 which are in clinical stage. Motif Bio plc is headquartered in London, UK.
Motif Bio Plc
201 TEMPLE CHAMBERS 3-7 TEMPLE AVENUE
LONDON X0 EC4Y0DT
CEO: Graham George Lumsden
Phone: 212-210-6248
Motif Bio plc is a biopharmaceutical company. It engaged in the research and development of antibiotics for serious and life-threatening infections caused by multi-drug resistant bacteria. The company's product pipeline includes Iclaprim, REVIVE-1 and REVIVE-2 which are in clinical stage. Motif Bio plc is headquartered in London, UK.
The current stock price of MTFB is 0.105 null. The price decreased by -4.63% in the last trading session.
MTFB does not pay a dividend.
MTFB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Motif Bio Plc (MTFB) has a market capitalization of 1.56M null. This makes MTFB a Nano Cap stock.
You can find the ownership structure of Motif Bio Plc (MTFB) on the Ownership tab.
ChartMill assigns a fundamental rating of 1 / 10 to MTFB. MTFB has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months MTFB reported a non-GAAP Earnings per Share(EPS) of -0.07. The EPS increased by 63.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -570.58% | ||
| ROE | N/A | ||
| Debt/Equity | -0.37 |